Structure via PubChem · Public domain (PubChem)
oteseconazole
Sign in to saveOteseconazole, a novel tetrazole containing orally bioavailable and selective inhibitor of fungal lanosterol 14α-demethylase (CYP51), has shown promising efficacy in the treatment of recurrent vulvovaginal candidiasis (RVVC).
Chemical data
- Formula
- C23H16F7N5O2
- Molecular weight
- 527.4 g/mol
- IUPAC name
- (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]propan-2-ol
- SMILES
- C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F
- InChIKey
- IDUYJRXRDSPPRC-NRFANRHFSA-N
- XLogP
- 4.2
- Polar surface area
- 86 Ų
- H-bond donors
- 1
- H-bond acceptors
- 13
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2022
- Admin. routes
- oral
- Indications
- tinea pedis, vulvovaginal candidiasis, fungal infectious disease, tinea unguium
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 527.119
Show 4 more facts
- canonical SMILES
- C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F
- chemical formula
- C₂₃H₁₆F₇N₅O₂
- isomeric SMILES
- C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F
- Commons category
- Oteseconazole
Sources (1)
via Wikidata · CC0
~3 min read
Encyclopedic overview
6 sectionsContents
- Society and culture
- Names
- Mechanism of action
- Adverse effect and interaction
- References
- External links
Oteseconazole, a novel tetrazole containing orally bioavailable and selective inhibitor of fungal lanosterol 14α-demethylase (CYP51), has shown promising efficacy in the treatment of recurrent vulvovaginal candidiasis (RVVC).
Marketed under the brand name Vivjoa, this medication was developed by Mycovia Pharmaceuticals and received approval for medicinal use from United States Food and Drug Administration (US FDA) in April 2022.
Excerpted from Wikipedia’s “oteseconazole” article, available under the CC BY-SA 4.0 licence.